University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

Christine Bestvina, MD, discusses the phase III KEYNOTE-407 trial in squamous non–small cell lung cancer.

Jyoti D. Patel, MD, discusses current immunotherapy options in stage IV non–small cell lung cancer.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the management of TKI-associated adverse events in kidney cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the importance of identifying molecular subsets in urothelial cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses ongoing immunotherapy trials in bladder cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses treatment approaches in non-muscle invasive bladder cancer (NMIBC).

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the management of patients with prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.